BD (Becton, Dickinson and Company)

BD finalized an initial pandemic order for 50 million needles and syringes to be delivered by the end of December 2020 to support the U.S. vaccination effort for COVID-19.

BD (Becton, Dickinson and Company) formed a public-private partnership with BARDA to invest $70 million in expanding manufacturing capacity for syringes and needles in Nebraska, with BARDA investing $42 million. BD also finalized an order for 50 million injection devices for COVID-19 vaccination.

BD (Becton, Dickinson and Company) formed a public-private partnership with BARDA to develop new manufacturing lines for syringes and needles in Nebraska. BARDA will invest $42 million into the $70 million capital project, and BD finalized an initial order for 50 million injection devices for COVID-19 vaccination.

BD (Becton, Dickinson and Company) opened its first Advanced Molding Center in Asia, built within its existing facility in Tuas, Singapore. The center is part of a US$5.2 million transformation and will increase plastic component production to 75 billion units, a 50% increase.

BD (Becton, Dickinson and Company) announced a $150 million investment in its existing Sumter County manufacturing facility in South Carolina, projected to create 125 new jobs over several years.

BD (Becton, Dickinson and Company) announced a $150 million investment in its existing Sumter County manufacturing facility, creating 125 new jobs.

BD broke ground on a $60 million, 69,000 sq. ft. expansion of its Columbus-East facility in Nebraska, transforming it into a flagship plastic injection molding plant. The project is expected to be completed by 2021.

BD (Becton, Dickinson and Company) announced it will invest $60 million to upgrade its Columbus-East facility in Nebraska into a plastic molding manufacturing center of excellence by 2021. The investment will add 69,000 sq. ft. and centralize North American plastic molding production.

BD (Becton, Dickinson and Company) announced a definitive agreement to acquire C. R. Bard, Inc. for $317.00 per share in cash and stock, total consideration $24 billion. The transaction is expected to be immediately accretive and generate cost synergies.